Abstract The microenvironment of a tumor is a highly complex milieu, primarily characterized by immunosuppression, abnormal angiogenesis, and hypoxic regions. These features promote tumor progression and metastasis, resulting in poor prognosis and greater resistance to existing cancer therapies. Galectin-1 is a β-galactoside binding protein that is abundantly secreted by almost all types of malignant tumor cells. The expression of galectin-1 is regulated by hypoxia-inducible factor-1 (HIF-1) and it plays vital protumorigenic roles within the tumor microenvironment. In particular, galectin-1 suppresses T cell-mediated cytotoxic immune responses and promotes tumor angiogenesis. However, since galectin-1 displays many different activities by binding to a number of diverse N-or O-glycan modified target proteins, it has been difficult to fully understand how galectin-1 supports tumor growth and metastasis. This review explores the importance of galectin-1 and glycan expression patterns in the tumor microenvironment and the potential effects of inhibiting galectin-1 as a therapeutic target for cancer treatment.
Introduction
Over the last century, the field of glycobiology has grown in significance and attracted a number of scientists from a variety of fields including immunology, virology, neurology, and oncology. The studies of lectin-glycan interactions are now one of the most rapidly expanding and promising areas for unveiling novel pathological features of disease, which cannot be explained solely through protein-protein interactions, and provide new avenues for research into carbohydrate-based treatments for diseases.
Galectins, formerly known as S-type lectins (to denote their sulfhydryl dependency), were first defined in 1994 as a galactoside binding lectin protein family [1, 2] . The carbohydrate recognition domains (CRDs), consisting of approximately 130 amino acids, are evolutionarily conserved and this structure is capable of recognizing β-galactosides, particularly N-acetyllactosamine-containing glycans. In contrast to cytokines or chemokines, galectins do not have restricted or unique cell surface receptors as their binding targets. Nevertheless, they mediate communication between cells via cell-cell or cell-extracellular components by binding to cell surface glyco-conjugated proteins or lipids. Currently, 15 mammalian galectins have been identified and are classified into three types based on their distinct biochemical structures: proto-type (galectin-1, -2, -5, -7, -10, -11, -13, -14, and -15), chimera-type (galectin-3), and tandem repeat-type (galectin-4, -6, 8, -9, and -12) [3] . Although a complete understanding of galectin interactions is still to be determined, the galectins have been extensively characterized functionally and shown to play fundamental roles in a diverse range of human disease including cancer. The expressions of major galectins by cancer cells are summarized in Table 1 .
The prototypic galectin-1 has become established as one of the most extensively studied pro-tumorigenic galectins. Accumulating evidence clearly shows that galectin-1 is involved in numerous essential cancer-related processes, including immunosuppression, angiogenesis, hypoxia, and metastasis. Although the other galectin families have been recognized as tumor promoting lectins, evidence for their involvement in tumorigenesis and the roles exerted by the other galectin-2 to -15 play has remained controversial. This review focuses on the diverse influences that galectin-1 confers to the dynamic behaviors of the tumor microenvironment and discusses potential strategies for cancer treatments targeting galectin-1 to block its function.
Structure and function of galectin-1
Galectin-1 protein possesses one CRD and can form a homo-dimer via non-covalent binding, providing it with cross-linking capability. The gene, LGALS1 (lectin galactoside binding soluble 1) encoding human galectin-1 (14.5 kDa) is located on chromosome 22 p12. The structure of the CRD in the galectin-1 protein is highly conserved among many vertebrates throughout evolution. It was reported that the DNA sequences from 27 vertebrate taxa show a highly conserved 4-exon gene structure [4] . Crystallography revealed that galectin-1 structures are formed by folding two anti-parallel β-sheets (F1 to F5 and S1 to S6, reviewed elsewhere [5] ) and the carbohydrate binding pockets are formed by several neighboring β-strands (S3, S4, S5, and S6) [2] . Since galectin-1 includes 6 cysteines, it can exist in either reduced or oxidized states. Oxidation of the cysteines in galectin-1 provides three intra-molecular disulfide bonds (Cys2-Cys130, Cys16-Cys88, and Cys42-Cys60), causing conformational changes that hinder lectin activity (CRD capacity) [6, 7] . The oxidized galectin-1 exists as a monomer and shows axonal regenerationpromoting activity [8, 9] , whereas reduced galectin-1 exists as a dimer with high CRD binding capacity.
Galectin-1 is overexpressed not only by a variety of cancer cell types, including malignant melanoma, ovarian, lung, breast, prostate, bladder, thyroid, head-neck, and colorectal cancers [10] , but also by activated vascular endothelial cells and regulatory T (Treg) cells in the host [11, 12] . In contrast to galectin-3, galectin-1 mainly functions as an extracellular promoting agent supporting tumor progression [13, 14] . Externalization of galectin-1 has been revealed using pulse-chase radio-labeling and it was shown that galectin-1 was secreted with a t 1/2 020 h from Chinese hamster ovary cells [15, 16] . However, similar studies of galectin-3 and fibroblast cells by pulse-chase analysis showed no secretion of galectin-3 [17] . These results are in agreement with a study of breast cancer cells where adherent cultures did not secrete galectin-3, whereas detached cells did [18] . A further study of a range of human cancer cell lines including breast, colon, and glioma also confirmed galectin-3 as a cytosolic protein that was not secreted extracellularly like galectin-1 [19] . Other studies have revealed that galectin-1 secretion proceeds by an unconventional protein export pathway independent of the classical endoplasmic reticulum to Golgi transport system [20] . Secreted galectin-1 is normally found extracellularly to exist in the reduced state where the CRD is functional and the protein is then involved in cell adhesion, migration, proliferation, cell survival, immunosuppression, and pro-angiogenic activities.
Extracellular galectin-1 could be a promising target for anti-cancer therapy, compared to the other galectins existing in the cytosol, because it can be more readily targeted to inhibit its pro-tumorigenic capacities by injection of therapeutic molecules that block the CRD. A number of studies have shown a relationship existing between the levels of galectin-1 in patients' blood and cancer progression. For example, higher galectin-1 levels were detected in the plasma from patients with late stage colorectal cancer than in healthy individuals and in addition, pre-surgery plasma in the colorectal cancer cases showed higher levels than early stage or post-surgery levels [21] . Furthermore, sera from metastatic breast cancer patients contained almost twice as much galectin-1-glycoprotein complexes compared with healthy individuals [22] . The elevated galectin-1 levels in plasma have been reported to correspond with poor prognosis of colorectal, head-neck squamous cell carcinoma and laryngeal squamous carcinoma [21, 23, 24] . Surprisingly, a recent report has shown that blood from breast cancer patients contains higher levels of galectins-2, -3, -4, and -9, compared to that of healthy individuals, whereas galectin-1 levels were found to be lower [25] . The serum levels of galectin-1 were measured in this study, instead of the plasma that is more commonly studied. Given that galectin-1 binds to platelets [26] causing cell aggregation and clotting, this may explain the lower levels of galectin-1 detected in the breast cancer patient sera used in this study. Furthermore, studies have shown that high levels of galectin-1 expressed broadly across primary tumor sections by immunohistochemistry [27] [28] [29] , suggesting most galectin-1 can bind to glycosylated components existing within the tumor microenvironment, rather than located in the blood stream. Thus, studies comparing levels of galectin-1 in cancer The effects of RNAi galectin knockdown
Galectin-1 Almost all types of cancer cells [121, 122] Upregulated in mouse plasma from melanoma, HNSCC, breast and colon cancer models and patients and it correlates with poor prognosis [21, 23, 24] Many types of human primary tumor tissues [28, 29] Increases sensitivity to anti-cancer drugs [123, 124] Human cancer tissues that were laser capture micro-dissected [27] Downregulated in serum from breast colon cancer patients [25] High levels in primary squamous cell carcinoma associated with metastasis [125] Modulates p53 transcriptional activity [124] HIF-1α stabilization upregulates LGALS1 expression [81] Particularly, highly expressed in metastatic cancer
Promotes T cell mediate anti-tumor immunity [52, 53, 126] Enhances neutrophil recruitment [127] Suppresses angiogenesis [52] Reduces metastasis [53, 89] Prostate cancer downregulates LGALS3 by methylating the promoter [133] Expression in cytoplasmic/nuclear [14, 134] Reduces melanoma growth and promote T cells [135] HIF-1a stabilization upregulates LGALS3 in human melanoma cells [83] High levels in primary tumor correlate with poor prognosis with metastasis (65 % of colorectal cancer patients) [136] Sensitizes to anti-cancer drugs [137, 138] Decreased expression in prostate cancer [139, 140] Reduces B16F10 migration and invasion with reduced MMP-1 [141] Galectin-4 Many types of cancer cell lines but not in breast, lung, and miscellaneous tumor cells [121, 142] Upregulated in breast and colon (serum) [25] Ovarian, colorectal, gastric, pancreatic, and appendiceal cancer [142] N/D Cytoplasmic expression [143] Galectin-7 Breast, colon, and lung but not in brain and miscellaneous tumor [121] N/D Hypopharyngeal squamous cell carcinoma (stages III and IV) [29] Inhibits murine lymphoma aggressiveness [144] Lymphoma cell lines [145] Induced by p53 [146] Galectin-8 Almost all types of cancer cell lines [121] Upregulated in breast and colon (serum) [25] Decreased in human colon tissue [147] N / D Galectin-9 Many types of cancer cell lines, but not in breast and lung cancer cells; downregulated in hematopoietic malignancies [121, 122] Upregulated in plasma from EBV + nasopharynegeal carcinoma xenografted mice or patients [148] High levels of expression show antimetastasis in breast cancer [149, 150] N/D [30] . Further studies revealed that cell surface glycoproteins on activated T cells were the primary receptors for extracellular galectin-1, including the T cell receptor (TCR), CD2, CD3, CD7, CD29, CD43, CD45, and CD95 [31, 32] . It has been shown that binding to the N-and O-glycan enriched T cell surface markers such as CD7, CD43, and CD45 is required for galectin-1 to induce the apoptosis of activated T cells [33] [34] [35] . However, the precise molecular mechanism for galectin-1-mediated apoptosis of activated T cells is still controversial. For example, one group has shown that galectin-1 binding triggered apoptotic pathways through induction of the activation protein-1 (AP-1) transcription factor and downregulation of mitochondrial Bcl-2 [36] . Galectin-1 has also been shown to induce activation of the c-Jun Nterminal kinase (JNK)/c-Jun/AP-1 pathway [37] . Galectin-1 has also been found to induce apoptosis by promoting TCRζ chain phosphorylation [38, 39] . In contrast, CD95 and caspase-8-mediated cell death signaling has also been suggested as another galectin-1-induced T cell apoptotic pathway [40] . Although the other galectins, including galectin-2, -3, and -9, have been recognized as pro-apoptotic lectins, the evidence supporting their activity in this regard remains unclear, compared to that of galectin-1. For example, galectin-2 has been shown to bind to β-integrins to induce apoptosis, but not to the T cell markers, CD3 and CD7, like galectin-1 [41] , indicating a more non-specific targeting of cell types by galectin-2. Other studies have shown that galectin-3 when overexpressed intracellularly in cancer cells protected them from apoptosis [42, 43] , whereas galectin-3 added extracellularly activated the mitochondrial apoptotic pathway by binding to the T cell markers, CD7 and CD29 [44] .
Galectin-1-induced T cell apoptosis depends on the glycosylation status of T cell surface molecules. Several studies have shown that glycan-modifying enzymes, such as glycosyltransferases and glycosidases, affect glycan expression patterns on T cells and associate galectin-1 binding. For example, expression of the glycosyltransferase, α2,6 sialyltransferase 1 (ST6Gal-I), incorporating α2,6 sialic acid onto terminal galactose residues, was shown to selectively modify the N-glycans on CD45 (leukocyte common antigen, Ly-5) thereby inhibiting galectin-1 binding [45] . Furthermore, CD45 + T cells that lack expression of N-acetylglucosaminyltransferase 1 (GCNT-1), which is required to make the core structure of O-glycans, were resistant to galectin-1-induced apoptosis. As another example, inhibiting glycosyltransferase N-acetylglucosaminyltransferase 5 (GnT-5), which produces the β-1,6-N-glycan branched structures on the TCR, reduced expression of β-1,6-NAc N-glycans and consequently promoted levels of TCR signaling. This resulted in augmented T helper type 1 (Th1) cell responses, significantly increasing cellular production of interferon (IFN)-γ [33, 46] . The changes in the numbers and structures of N-glycans could selectively control the levels of T cell growth activation to regulate the immune system [46] . The TCR is recognized as a highly glycosylated molecule containing β-1,6-N-glycan branched structures, whereas inhibitory receptors such as the transforming growth factor-β receptor (TGF-βR) and cytotoxic T lymphocyte antigen-4 (CTLA-4), show reduced levels of β-1,6-N-glycans [32] . Thus, galectin-1 may be a very important molecule for selectively regulating the activation and survival of effector T cell subsets via the differentially expressed and glycosylated surface receptors. + Treg cells [12] . Another study has shown that activation of Treg cells upregulates the levels of galectin-1 production and secretion [12] . Taken together, these findings now make it clear that galectin-1 is a significant factor contributing to the control of Treg cell immunosuppressive mechanisms.
The other immunosuppressive role of galectin-1 involves the CTLA-4 T cell inhibitory surface molecule. CTLA-4, expressed on activated T cells, B cells, and Treg cells, induces inhibitory signals through interactions with CD80/ CD86 (B7) co-stimulatory molecules expressed on the antigen presenting cells (APCs). This inhibitory CTLA-4/B7 interaction overrides and is much stronger than the alternative pro-inflammatory co-stimulating axis represented by CD28/B7. Although CTLA-4 contains only two N-glycans per molecule, galectin-1 bound N-glycans enhance the CTLA-4 cell surface membrane retention on effector T cells, resulting in amplified and sustained signaling of T cell growth arrest [32] .
Th2 cells are resistant to galectin-1 binding, although Th1 and Th2 cells contain similar levels of galectin-1 binding receptors such as CD7, CD43, and CD45 [48] . Further study revealed that only Th2 cells show high levels of ST6Gal-I enzyme activity [48] , indicating that Th2 cell surface N-glycans are covered by sialic acid, protecting them from galectin-1 binding. Th17 cells were found to share a common glycan motif with Th1 cells. Therefore, similar to Th1 cells, Th17 cells are also sensitive to galectin-1-induced apoptosis [48] . Activated T cells that were cultured with galectin-1 produce higher amounts of the Th2 cytokines including IL-4, IL-5, IL-10, and IL-13 [47, 48] . Galectin-1 treatment in vivo greatly increases IL-10 production inducing T cells that suppress autoimmune inflammation [49] . These observations are consistent with studies showing that galectin-1 knockout mice (Lgals1
) produce more IFN-γ and IL-17 than wild type mice [48] .
Effector memory T cells (CD8 + CD45RO + CCR7 − ) are known to reduce O-glycan structures on their surfaces [50] , suggesting that memory T cells could thereby escape the galectin-1-mediated apoptosis [51] . However, it is not yet known whether galectin-1 affects memory T cell populations directly or indirectly when the activated Th1, Th17 cells, or CTLs are undergoing galectin-1-induced apoptosis.
As discussed in the previous sections, the immunosuppressive activities of galectin-1 should be taken into account when it comes to cancer immunotherapy. In contrast to the other immunosuppressive cytokines, chemokines, or transcription factors, galectin-1 binds to a number of different targets expressing N-or O-glycans and triggers immunoinhibitory signaling. Given the complexity of galectin-1 binding targets, it has not been straightforward to clearly identify the mechanism for galectin-1-mediated tumor immune evasion. However, given the overall evidence from the past research, it has now become obvious that galectin-1 plays significant roles in tumor cell immune escape from damage caused by the immune system. Recently, we and others have shown that knockdown of galectin-1 expression in tumor cells by using short hairpin RNA (shRNA) increased the levels of effector T cell infiltration into tumors, leading to suppressed tumor growth rates [52, 53] . However, it should be noted that galectin-1 also affects other cancer processes such as angiogenesis. It has been described that abnormally re-arranged tumor vasculature frequently inhibited effector T cell infiltration into tumors. Therefore, in order to increase immune cell infiltration into the tumor stroma, it is important to first manipulate and normalize the tumor endothelium and angiogenesis [54] [55] [56] . Therefore, in addition to the more direct ways of immunosuppression on the immune cells themselves, galectin-1 may also systemically suppress or avoid anti-tumor immune cell functions by preventing the accessibility of cytotoxic T cells targeting the tumor. The following section describes the galectin-1 influence on vascular endothelial cells and tumor angiogenesis.
The role of galectin-1 in tumor angiogenesis
During cancer progression, the other prominent feature of galectin-1 is its pro-angiogenic activity. Tumor angiogenesis refers to the formation of new blood vessels induced by tumor cell-secreted factors such as vascular endothelial growth factor (VEGF). Essential for the continued growth of solid tumors is that new blood vessels must form to provide and supply sufficient oxygen and nutrients. Several steps are required during the tumorigenic neovascularization, including destabilization of the existing basal membrane and extracellular matrix by proteases such as metalloproteinases (MMPs), thereby stimulating vascular endothelial cells to promote the formation of new capillaries [57] . The abnormalities of the tumor vasculature have already been well reviewed elsewhere [57, 58] . Tumor blood vessels are relatively immature and express lower levels of adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin on the vascular endothelial cells in the tumor. The structurally abnormal blood vessels also contribute to the aberrantly pressurized blood flow and a high tumor vascular permeability, causing an impaired lymphatic drainage or "leakiness." This chaotically re-arranged tumor vasculature prevents effector T cell trafficking into the tumors [59] .
The roles of galectin-1 in tumor angiogenesis were found to include stimulating vascular endothelial cell growth as well as to provide physical support for the newly formed capillaries. In the tumor microenvironment, galectin-1 is present in abundance as indicated by elevated expression in both activated endothelial cells and the tumor cells themselves [60] . Thijssen et al. reported that tumor cell-derived galectin-1 was taken up by the endothelial cells in Lgals1 −/− mice, stimulating endothelial cell proliferation and migration by promoting H-Ras signaling via the Raf/mitogenactivating protein kinase (MAPK)/extracellular signalregulated kinase (MEK)/ERK pathway [61] . This finding implies that the high levels of extracellular galectin-1 produced by tumor cells may have greater impact on promoting angiogenic activities than the levels of endothelial cellderived host galectin-1. In fact, when only tumor-derived galectin-1 levels were knocked down by shRNA transfection, tumor growth rates were significantly delayed with reduced angiogenesis within tumors [52, 53] . Furthermore, galectin-1 regulates gene expression associated with tumor angiogenesis. For example, downregulating galectin-1 in the oligodendroglioma hs683 cell line was associated with the reduced expression of the brainexpressed X-linked gene 2 (BEX2, a tumor suppressor gene) impairing endothelial cell tube formation (a model for mimicking vasculogenesis in vitro), glioma cell adhesion and invasion as well as reducing the tumor angiogenesis in vivo [62] .
Galectin-1 also promotes the physical interactions between endothelial cell-cell or cell-extracellular matrix, helping to construct new blood capillaries via its homodimeric cross-linking property. Vascular endothelial cells are surrounded by considerable amounts of N-glycans on their surfaces. In addition, the extracellular matrix in the tumor stroma contains high levels of laminin and fibronectin, which are known to be significant galectin-1 binding targets [63, 64] . These components can be bound as either cell-cell or cell-extracellular matrix interactions via galectin-1. We have previously demonstrated that adding exogenous galectin-1 increased the capillary-like tube forming capacity of endothelial cells within basal membrane Matrigel cultures [52] . This finding supports the hypothesis that the extracellular galectin-1 structurally influences and promotes tumor angiogenesis by reinforcing and stabilizing connections of vascular endothelial cells and extracellular matrix interactions within the tumor microenvironments.
A recent study showed that neuropilin-1, which is a transmembrane co-receptor of vascular endothelial growth factor receptors (VEGFRs), is highly O-and N-glycosylated on endothelial cells and identified neuropilin-1 as a novel target for galectin-1 [65] [66] [67] . Binding galectin-1 to neuropilin-1 on the vascular endothelial cells promotes VEGFR-2 phosphorylation and mediates migration and adhesion of the endothelial cells [67] . This finding indicates yet another means for galectin-1 promoting tumor angiogenesis. Furthermore, recent studies described that targeting neuropilin-1 using a tumor-homing peptide, iRGD, greatly increased the permeability of the tumor vasculature, thereby enhancing the delivery of anti-cancer drugs into tumors [68] . If galectin-1 affects vascular permeability by affecting neuropilin-1 function, then targeting galectin-1 may very likely be effective for improving the efficacy of chemotherapy against cancer.
Our findings have indicated that galectin-1 may also protect vascular endothelial cells from the oxidative stress existing within the tumor microenvironment. For example, in vitro studies, in which exogenous reduced galectin-1 was added, the levels of human endothelial cell apoptosis induced by hydrogen peroxide were significantly reduced, as well as allowing for the recovery in the levels of endothelial cell proliferation [52] . This may be explained by the fact that the galectin-1 structure contains six cysteines which are capable of absorbing oxidative stress via sulfhydryl oxidation [7] . However, the detailed mechanisms for this process need to be further examined.
Galectin-1 expression in tumor hypoxia
The chaotically arranged capillaries and rapid cell growth within tumors frequently leads to oxygen insufficiency within the tumor microenvironment resulting in hypoxic conditions [69] . The intratumoral hypoxia promotes production of reactive oxygen species (ROS) causing stabilization of hypoxia inducible factor-1α (HIF-1α), which then forms a transcriptional heterodimer with its binding partner HIF-1β [70] . The stabilized HIF-1α/β complex promotes the expression of other pro-tumorigenic proteins, such as VEGF and the glucose transporter-1 (GLUT-1), and plays a pivotal role in tumor progression, metastasis, angiogenesis, metabolic switching to aerobic glycolysis (the "Warburg effect"), and resistance to chemotherapy. In particular, several studies have demonstrated that intermittent or "cycling hypoxia," rather than regions of chronic hypoxia, causes greater levels of HIF-1α stabilization within a tumor microenvironment, resulting in promotion of tumor angiogenesis and radiotherapy resistance [71] [72] [73] . In the hypoxia-exposed areas, the tumor cells are selected to undergo development into a more aggressive phenotype that leads to rapid progression and poor prognosis, and this hypoxia-induced phenotype often becomes resistant to subsequent radiation and chemotherapy [74] .
Hypoxia has been recognized to present an immunosuppressive factor [75] . By producing HIF-1α deficient CD4 + and CD8 + T cells (defective in their ability to respond to hypoxia), it was shown that these cells then had greater capacity to proliferate and to produce IFN-γ [76] . Moreover, tumor hypoxia has been shown to decrease the tumor susceptibility to CTL-mediated cell lysis as a result of HIF-1α stabilization and STAT3 phosphorylation [77] . As indirect mechanisms for hypoxia-mediated immunosuppression, CD39 (ecto-apyrase) and CD73 (ecto-5′-nucleotidase), which respectively convert ATP and ADP into adenosine, are upregulated during hypoxia [78] . The increased soluble adenosine binds to the A 2A receptor on the effector T cells, but not on Treg cells, to induce growth inhibitory signals [79] . Furthermore, hypoxia-exposed tumor cells produce greater levels of the CC-chemokine ligand 28 (CCL28), which selectively attracts and recruits the Treg cells into the tumor stroma [80] . All these effects will result in greater tumor-mediated immunosuppression.
Interestingly, the expression of galectin-1 is also upregulated by the level of HIF-1α stabilization within tumors. The hypoxia-responsive elements are located at −441 to −423 bp upstream of the transcriptional start site of the Lgals1 gene and are essential for HIF-1-mediated galectin-1 expression [81] . Several studies have shown that hypoxia-exposed cancer cells produce the higher levels of galectin-1, which correlated with their levels of HIF-1α, as well as those of carbonic anhydrase IX (CA IX), whose expression is a late marker of hypoxia [81, 82] . These studies also showed that knocking down the expression of galectin-1 reduced hypoxia-induced invasion and migration of colorectal cancer cell lines. These data indicate that the increased galectin-1 by hypoxia is related with poor prognosis of cancer patients. It has been found that mRNA of galectin-3 was also upregulated within hypoxic regions of murine and human melanomas, although it remains unclear whether the hypoxia-induced galectin-3 mRNA relates to the poor prognosis of cancer patients [83] .
In summary at this point, all the above findings suggest novel mechanisms for the pro-tumorigenic actions of galectin-1 in dynamically altering the tumor microenvironment (Fig. 1) . Overall, the picture is emerging that the sequence of events in an abnormally growing solid tumor will firstly occur as events precipitated by the onset of intratumoral hypoxia, followed by ROS production and HIF-1α stabilization. The stabilized HIF-1α induces galectin-1 expression, which will help vascular endothelial cells to create new capillaries by activating endothelial cell proliferation and migration, reinforcing cell-cell and cell-extracellular matrix and protecting them from the oxidative stress caused by increased ROS levels existing within the tumors. Meanwhile, galectin-1 is also likely to be contributing to protection of the immature tumor region from immune attack by inducing apoptosis of activated CD4 + and CD8 + effector T cells. This is further supported by the fact that hypoxia-exposed necrotic tumor regions can be characterized by the distinct absence of detectable effector T cells and their tumor-specific responses [84] .
Galectin-1 and metastasis
Tumor metastasis involves a number of processes including the invasion of the tumor cells into the surrounding tissues, intravasation, dissemination via the blood or lymph vessels, extravasation, and colonization into distant organs. The interaction of the circulating cancer cells with endothelium within a secondary organ site is a critical first step required for metastasis formation. This step involves tumor-endothelial cell Fig. 1 Summary of galectin-1 pro-tumorigenic functions in a tumor microenvironment. a Intratumoral hypoxia developing during tumor progression increases ROS production in the hypoxia-exposed regions. ROS inhibits prolyl and asparginyl hydoxylases resulting in an increased level of HIF-1α. Stabilized HIF-1α incorporates with HIF-1β and this complex binds DNA to promote transcription of galectin-1. b Secreted reduced galectin-1 may absorb ROS to reduce the oxidized stress and will be converted into the oxidative state with three disulfide bounds. c Free galectin-1 binds to vascular endothelial cell surfaces and promotes tumor angiogenesis through promoting endothelial cell proliferation and migration and reinforcing interactions of cell-cell or cell-extracellular matrix (laminin and fibronectin). d When binding to effector T cells, galectin-1 induces apoptosis in effector Th1/Tc by binding to surface glycoproteins such as CD7, CD43 and CD45. e CTLA-4 expressed on Th1 cells is retained on the surface by galectin-1 binding and amplifies the inhibitory signals arresting effector T cells. f Inhibitory effects of Treg cells, which also express galectin-1, are activated by galectin-1 (detail mechanisms not known). g Circulating cancer cells are surrounded by galectin-1, protecting them from effector T cell surveillance. h The attachment of the survived circulating cancer cells to the endothelium can be enhanced by galectin-1, resulting in initiation of metastasis. i Galectin-1 binding to neuropilin-1 activates VEGFR-2 phosphorylation and promotes angiogenesis interactions occurring between various surface adhesion molecules including integrins, ICAM-1, VCAM-1, or selectins [85, 86] . In addition, galectin-1 has been shown to promote the adhesion of hepatocellular carcinoma, melanoma, ovarian, and prostate cancer cells to the extracellular matrix [63, 87, 88] . Our recent studies have uncovered roles for CD44 and CD326 on murine breast and colon cancer cells as galectin-1 binding targets that contribute to attachment of cancer cells to extracellular matrix and endothelial cells [89] . Additionally, galectin-1 activates platelets to induce P-selectin and the membrane glycoprotein complex (GPIIb/IIIa), leading to their aggregation [26] . Galectin-1 on the circulating cancer cell surfaces may bind to these molecules and form plateletcancer cell complexes. The aggregated cancer cell-platelet clusters are likely arrested in capillaries at the secondary organs, and then can develop into metastases. However, several galectins have been identified to have both adhesive and de-adhesive properties, depending on the tumor cell types from which they are derived [90] . Although further studies will be required to determine the exact roles and contribution of galectin-1, we and others have shown that knockdown of galectin-1 in murine breast, colon, and Lewis lung cancer cells significantly reduced their lung metastatic potential [53, 91] . In these studies, significantly increased levels of peripheral effector T cell function were also observed, as well as reduced levels of tumor angiogenesis. Therefore, because of its multiple roles in the metastasis process, targeting galectin-1 may provide an effective means for inhibiting the spread of cancer.
Other functions of galectin-1 in the tumor microenvironment
Most recently, galectin-1 was shown to stimulate tumor associated dendritic cells (TADCs) that are known to inhibit effector T cell responses in the tumor microenvironment [92] . The galectin-1-stimulated TADCs produced large amounts of heparin-binding EGF-like growth factor (HB-EGF), which binds to EGF receptors and stimulates carcinoma cell growth. It has been found that galectin-1 knockdown in Lewis lung carcinoma cells decreased their expression of HB-EGF and increased mouse survivals [92] .
Galectin-1 may be related to the radio-resistance of tumor cells. The interaction between galectin-1 and H-Ras following irradiation was shown to enhance DNA repair and proliferation in cervical cancer cells [93] , which is associated with the induction of tumor radio-resistance. Prior to activation, H-Ras is distributed equally between lipid raft and non-raft domains in the plasma membrane. However, upon GTP loading, HRas-GTP undergoes lateral segregation to non-raft domains where it initiates intracellular signaling [94] . Galectin-1 appears to form the inner membrane lattice network, acting as a necessary platform for the H-Ras induced activation of the Raf-1/Phosphoinositide 3 kinase (PI3-K) growth signaling pathway [95] . This may occur through a hydrophobic pocket in galectin-1, independent of the CRD, which is capable of binding to the farnesyl group of H-Ras, stabilizing the translocation of H-Ras-GTP onto the galectin-1 membrane microdomain or "raft" [96, 97] . Given the fact that hypoxia is known to induce radio-resistance and increase galectin-1 expression, the interaction between galectin-1 and H-Ras may play a significant role in tumor hypoxia-mediated radiotherapy resistance by stimulating H-Ras signaling and DNA repair.
Inhibitors of galectin-1 functions
While the natural disaccharide, lactose (Galβ1-4Glc) has commonly been used to inhibit galectin function in numerous previous reports, it is easily catalyzed into monosaccharides by the enzyme β-galactosidase and requires high concentrations (at least 10 mM) to occur before it can effectively inhibit the galectin CRD. Therefore, many chemistry-based studies have undertaken to develop novel synthetic compounds that will more effectively target and inhibit the galectin-1 CRD. Many of these are reviewed in this section and are summarized in Table 2 .
Thiodigalactoside (TDG) is one of the simplest disaccharidebased synthetic compounds which is commercially available. We and others have used TDG to investigate the effects of galectin-1 inhibition in cancer and immunology studies. TDG has a relatively higher affinity with a K d of 43 μM for galectin-1 and contains a sulfur-bond instead of an oxygen-bond linking, providing a non-metabolizable inhibitor [98, 99] . Although TDG treatment in vivo showed notable anti-tumor and antimetastatic effects [52, 89] , high doses (40 to 120 mg/kg) and frequent injections (every 2 to 3 days) were required for this therapy to show effect. This may be explained by the relatively rapid clearance of TDG via renal excretion because of its small molecular size (MW of TDG0358.36). In addition, the affinity for the galectin-1 CRD may not be strong enough to hold galectin-1-TDG in complex for the long term (i.e., in an irreversibly bound state). In order to increase the affinity for the galectin-1 CRD, Nilsson et al. have developed TDG derivatives with two aromatic amide substituents [98, 99] . These compounds showed greater affinity for the galectin CRD through an increased interaction with an arginine residue (Arg74 in the structure of human galectin-1). Another study showed that replacing galactose with a talose (the C2 epimer of galactose) scaffold, followed by hydrophobic group derivatization off the 2′-O link increased the opportunity for additional protein-ligand interactions and one resulting compound, methyl 3-deoxy-2-Otoluoyl-3-N-toluoyl-β-D-talopyranoside, showed a much higher affinity for galectin-1 than for galectin-3 [100] .
The effects of galectin-1 inhibition on angiogenesis have been investigated by using a small β-peptide (Anginex) The clone of mAb: 25 C1 [101] [102] [103] . Anginex inhibits microvessel formation in vivo but does not affect the major pre-existing blood vessels [104] , indicating its tumor specificity. In one study, Anginex was reported to significantly decrease the membrane-bound HRas, but not K-or N-Ras with a specific reduction of the Raf/Mek/Erk signal activation in vascular endothelial cells [61] . In contrast, it has been demonstrated that Anginex markedly increased the binding affinity of galectin-1 to glycoproteins analyzed by fluorescence anisotropy [105] . Natural product-based compounds have also been investigated with modified citrus pectin (MCP), which is believed to bind galectin-3 [106, 107] , reported to show anti-cancer and antimetastatic effects [107, 108] . Although the precise mechanisms for these effects are not known, they probably also involve inhibition of galectin-1 function because of the broad carbohydrate structures providing a wide binding specificity of MCP. Moreover, an α-galactomannan, derived from Cyamopsis tetragonoloba (guar gum), has also been shown to bind to galectin-1 analyzed by NMR [109] . Davanat, which is a chemically modified galactomannan, is currently being investigated in human Phase II clinical trial against metastatic colorectal cancer (Galectin Therapeutics: http://www.galectintherapeutics.com/).
A recent study has demonstrated that targeting N-acetyllactosamine synthesis on T cell surface membrane glycoproteins with a metabolic inhibitor, peracetylated 4-fluoro-glucosamine (4-F-GlcNAc) significantly inhibited the growth of B16F10 melanoma and EL-4 lymphomas with the enhanced antitumor immune responses including IFN-γ production and CTL cytotoxicity [110] .
In terms of research and development of a specific galectin-1 inhibitor, cross-reactivity within the other galectin subfamilies may be a problem. Sequence identity among most galectin CRDs ranges from about 20 % to 50 %. Although Hirabayashi et al. showed different carbohydrate-binding preferences for individual galectins, they all showed high affinity to the same basic saccharide backbone in their studies [111] .
In order to advance galectin-1 CRD specific inhibitors as a cancer therapy, it will be essential to further explore and define the ligand binding properties for the CRD. The glycosylation status of the various galectin-1 ligands can differ depending on the type of cell, tissue or physiological condition. For example, previous studies showed that CD44 expressed on T cells is not a galectin-1 binding target [112] , whereas our recent data have shown that CD44 expressed on the surface of breast cancer cells does act as a galectin-1 binging target [89] . This may be due to the difference in glycosylation status between CD44 on T cells and cancer cells. Increased golgi β1,6-N-acetylglucosaminiltransferase V (Mgat5) expression occurs during carcinogenesis, resulting in β1,6-GlcNAc-branched complex N-glycans on cell surface glycoproteins [113] . A recent study showed that only highly metastatic prostate cancer cell lines (PC-3 and LNCaP) expressed considerable amounts of Mgat5b products (β1,6-GlcNAc-branched glycans), whereas they were not detectable on the non-metastatic cell line (DU-145 and LuCaP 23.1) [114] . This result indicates that the glycosylation status can also differ even within the same type of cancer cells. Moreover, the engagement of galectin-1 binding candidates with other ligands may alter the capacity of galectin-1 ligand binding. For example, hyaluronan, a large non-sulfated glycosaminoglycan (MW0up to 1×10 6 ), may inhibit galectin-1 binding when attached to the CD44 as found on epithelial cells.
Targeting galectin-1 using combination treatment
Despite improvements in the overall survival of cancer patients more recently with the use of such common anti-cancer therapies as chemotherapy, radiotherapy, and immunotherapy, the individual use of these common therapies is often insufficient to overcome cancer. Hence, this leads to the proposal to target other aspects of cancer, such as tumor angiogenesis or intratumoral hypoxia-induced pro-tumorigenic signaling. Combination treatment is one of the key strategies for improving the overall efficacies of cancer therapy. A number of studies have examined several combination treatments and found that regulating tumor angiogenesis by anti-angiogenic drugs or normalization of tumor vasculature could improve outcomes of chemotherapy or immunotherapy [54, 56, 115] .
Several studies have investigated the effects of treatments combining galectin-1 inhibition with other cancer therapies. For example, Anginex was shown to improve chemotherapy outcomes in xenografted human ovarian cancer in mice [116, 117] . Additionally, Anginex conjugated with an anti-cancer drug effectively reduced xenografted human ovarian cancer growth [118] . These studies indicate that targeting galectin-1 may improve the anti-cancer drug delivery by disrupting vascular endothelial cells. It is also proposed that simultaneously targeting galectin-1 may protect the stimulated anti-tumor targeted effector T cells induced by immunotherapy from galectin-1-induced apoptosis. Moreover, previous data showed that endothelial galectin-1 inhibits T cell transendothelial migration [119] . These observations imply that targeting galectin-1 may increase effector T cell attachment onto vascular endothelial cells and promote the levels of tumor infiltrating effector T cells. Therefore, we have investigated the hypothesis that galectin-1 inhibition may provide synergetic effects with other immunotherapies. In a combination study together with a low dose anti-CTLA-4 mAb (9H10), the galectin-1 inhibitor TDG significantly increased the survival of tumor bearing mice, compared to CTLA-4 mAb treatment alone (unpublished data). Moreover, combining TDG therapy with a cancer whole cell vaccine has also provided greater induction of tumor-specific CD8 + T cell cytotoxicity and prolonged mouse survival [120] . Although it is necessary to demonstrate the precise contributions that galectin-1 inhibition provides, particularly for its effects on hypoxiarelated signaling, these pre-clinical data indicate that galectin-1 inhibition as an adjuvant treatment will be effective for improving the potency of many other immunotherapies.
Conclusion and future directions
Extensive studies over the last two decades have highlighted galectin-1 as an important protein in cancer biology, which has significantly increased our understanding of key mechanisms involved in cancer and metastasis progression. As discussed in this review, hypoxia-inducible galectin-1 promotes tumor growth and metastasis by promoting immune evasion and angiogenesis. This is mediated through the binding of galectin-1 to various glycoproteins expressed on a number of different cell types. These properties make galectin-1 a prime therapeutic target in the regulation of cancer disease progression.
Exploitation of this therapeutic opportunity in galectin-1 biology requires a comprehensive understanding behind the precise mechanisms of galectin-1 function as essential. Salient lines of enquiry include the identification of other galectin-1 binding targets that may be involved in cancer progression, and the effect of diverse glycosylation states differing between different cancer types on galectin-1 function. In order to clarify these queries, it will be necessary to understand and determine the glycan expression patterns and the glycan modifying enzyme activities in different cell types. In addition to the aforementioned roles in cancer biology and disease progression, galectin-1 activity may be an important aspect of cancer stem cells. Given the relationship between intratumoral hypoxia, metastasis, and galectin-1 expression, determining the contribution of galectin-1 to cancer stem cell maintenance within tumors represents an intriguing prospect. The fact that the main components forming the cancer stem cell niche, namely laminin and fibronectin, are galectin-1 binding proteins increases this appeal. Elucidation of these mechanisms and roles will further our understanding of cancer biology and aid in the development of effective galectin-1 inhibitors, a novel and attractive target for cancer therapeutics.
